Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 33. Отображено 33.
27-06-2013 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20130165390A1
Принадлежит: Millennium Pharmaceuticals, Inc.

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 3. The compound of claim 2 , wherein each of Rand Rindependently is hydrogen claim 2 , Caliphatic claim 2 , or —(CH)—COH;and p is 0, 1, or 2.4. The compound of wherein P is R—C(O)— claim 3 , R—O—C(O)— claim 3 , R—N(R)—C(O)— claim 3 , R—S(O)— claim 3 , or R—N(R)—S(O)—;{'sup': c', 'D', '1', 'D', '1', '2c, 'sub': 1-6', '1-6, 'claim-text': [{'sup': 1', '3a', '3b', '5', '5, 'sub': '1-6', 'Tis a Calkylene chain substituted with 0-2 independently selected Ror R, wherein the alkylene chain optionally is interrupted by —C(R)═C(R)—, —C≡C—, or —O—;'}, {'sup': 'D', 'Ris a substituted or unsubstituted mono- or bicyclic ring system;'}, {'sup': 2c', '5', '6', '6', '6', '4', '4', '4', '5', '4', '4', '4', '6', '4', '6', '4', '4', '5', '4', '5', '5', '4, 'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'Ris halo, —ORe, —SR, —S(O)R, —SOR, —SON(R), —N(R), —NRC(O)R, —NRC(O)—N(R), —NRCOR, —N(R)SOR, —N(R)SON(R), —O—C(O)R, —OC(O)N(R), —C(O)—R, —COR, or —C(O)N(R);'}, {'sup': 3a', '4, 'sub': 1-4', '2', '1-4', '2', '2', '1-4', '2', '1-4, 'each Rindependently is selected from the group consisting of —F, —OH, —O(Calkyl), —CN, —N(R), —C(O)(Calkyl), —COH, —CO(Calkyl), —C(O)NH, and —C(O)—NH(Calkyl);'}, {'sup': 3b', '3a', '7', '3b, 'sub': '1-3', 'each Rindependently is a Caliphatic substituted or unsubstituted with Ror R; or two substituents Ron the same carbon atom, taken together with the carbon atom to which they are attached, form a 3- to 6-membered cycloaliphatic ring;'}, {'sup': '7', 'each Ris a substituted or unsubstituted aromatic group; and'}], 'Ris selected from the group consisting of Caliphatic, Cfluoroaliphatic, —R, -T-R, and -T-R;'}{'sup': '4c', 'sub': 1-4', '1-4', '6-10', '1-4, 'Ris hydrogen, Calkyl, Cfluoroalkyl, or ...

Подробнее
16-01-2014 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20140018301A9
Принадлежит: Millennium Pharmaceuticals, Inc.

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 3. The compound of claim 2 , wherein each of Rand Rindependently is hydrogen claim 2 , Caliphatic claim 2 , or —(CH)—COH;and p is 0, 1, or 2.4. The compound of wherein P is R—C(O)— claim 3 , R—O—C(O)— claim 3 , R—N(R)—C(O)— claim 3 , R—S(O)— claim 3 , or R—N(R)—S(O)—;{'sup': c', 'D', '1', 'D', '1', '2c, 'sub': 1-6', '1-6, 'claim-text': [{'sup': 1', '3a', '3b', '5', '5, 'sub': '1-6', 'Tis a Calkylene chain substituted with 0-2 independently selected Ror R, wherein the alkylene chain optionally is interrupted by —C(R)═C(R)—, —C≡C—, or —O—;'}, {'sup': 'D', 'Ris a substituted or unsubstituted mono- or bicyclic ring system;'}, {'sup': 2c', '5', '6', '6', '6', '4', '4', '4', '5', '4', '4', '4', '6', '4', '6', '4', '4', '5', '4', '5', '5', '4, 'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'Ris halo, —OR, —SR, —S(O)R, —SOR, —SON(R), —N(R), —NRC(O)R, —NRC(O)—N(R), —NRCOR, —N(R)SOR, —N(R)SON(R), —O—C(O)R, —OC(O)N(R), —C(O)—R, —COR, or —C(O)N(R);'}, {'sup': 3a', '4, 'sub': 1-4', '2', '1-4', '2', '2', '1-4', '2', '1-4, 'each Rindependently is selected from the group consisting of —F, —OH, —O(Calkyl), —CN, —N(R), —C(O)(Calkyl), —COH, —CO(Calkyl), —C(O)NH, and —C(O)—NH(Calkyl);'}, {'sup': 3b', '3a', '7', '3b, 'sub': '1-3', 'each Rindependently is a Caliphatic substituted or unsubstituted with Ror R; or two substituents Ron the same carbon atom, taken together with the carbon atom to which they are attached, form a 3- to 6-membered cycloaliphatic ring;'}, {'sup': '7', 'each Ris a substituted or unsubstituted aromatic group; and'}], 'Ris selected from the group consisting of Caliphatic, Cfluoroaliphatic, —R, -T-R, and -T-R;'}{'sup': '4c', 'sub': 1-4', '1-4', '6-10', '1-4, 'Ris hydrogen, Calkyl, Cfluoroalkyl, or ...

Подробнее
02-01-2020 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: US20200002361A1
Принадлежит: Millennium Pharmaceuticals Inc

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
04-01-2018 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20180002350A1
Принадлежит:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 2. The process of claim 1 , wherein the reaction of step (1) or step (3) or both is conducted in the presence of a peptide coupling reagent.3. The process of claim 2 , wherein the peptide coupling reagent is selected from the group consisting of a carbodiimide reagent claim 2 , phosphonium reagent claim 2 , and uronium reagent.4. The process of claim 3 , wherein the peptide coupling reagent is selected from one or more of the group consisting of dicyclohexylcarbodiimide (DCC) claim 3 , 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) claim 3 , benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) claim 3 , and O-(1H-benzotriazol-1-yl)-N claim 3 ,N claim 3 ,N′ claim 3 ,N′-tetramethyluronium tetrafluoroborate (TBTU).5. The process of claim 1 , further comprising converting the carboxylic acid moiety of compound (i) to an activated ester or acid halide prior to the reaction of step (1).6. The process of claim 5 , wherein said activated ester or acid halide is an O—(N-hydroxysuccinimide) ester.7. The process of claim 1 , wherein the reaction of step (3) is conducted in the presence of a solvent.8. The process of claim 7 , wherein the solvent is tetrahydrofuran.9. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an aqueous mineral acid.10. The process of claim 9 , wherein the mineral acid is hydrochloric acid.11. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an organic boronic acid acceptor.12. The process of claim 11 , wherein the organic boronic acid acceptor is i-BuB(OH).13. The process of claim 1 , wherein the reaction of step (5) is conducted in the presence of a solvent selected from the group consisting of ...

Подробнее
13-01-2022 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20220009948A1
Принадлежит:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 2. The process of claim 1 , wherein the reaction of step (1) or step (3) or both is conducted in the presence of a peptide coupling reagent.3. The process of claim 2 , wherein the peptide coupling reagent is selected from the group consisting of a carbodiimide reagent claim 2 , phosphonium reagent claim 2 , and uronium reagent.4. The process of claim 3 , wherein the peptide coupling reagent is selected from one or more of the group consisting of dicyclohexylcarbodiimide (DCC) claim 3 , l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) claim 3 , benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) claim 3 , and O-(1H-benzotriazol-1-yl)-N claim 3 , N claim 3 , N′N′-tetramethyluronium tetrafluoroborate (TBTU).5. The process of claim 1 , further comprising converting the carboxylic acid moiety of compound (ii) to an activated ester or acid halide prior to the reaction of step (1).6. The process of claim 5 , wherein said activated ester or acid halide is an O—(N-hydroxysuccinnimide) ester.7. The process of claim 1 , wherein the reaction of step (3) is conducted in the presence of a solvent.8. The process of claim 7 , wherein the solvent is tetrahydrofuran.9. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an aqueous mineral acid.10. The process of claim 9 , wherein the mineral acid is hydrochloric acid.11. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an organic boronic acid acceptor.12. The process of claim 11 , wherein the organic boronic acid acceptor is t-BuB(OH).13. The process of claim 1 , wherein the reaction of step (5) is conducted in the presence of a solvent selected from the group consisting of ethyl ...

Подробнее
04-02-2016 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20160031913A1
Принадлежит:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 2. The process of claim 1 , wherein the reaction of step (1) or step (3) or both is conducted in the presence of a peptide coupling reagent.3. The process of claim 2 , wherein the peptide coupling reagent is selected from the group consisting of a carbodiimide reagent claim 2 , phosphonium reagent claim 2 , and uronium reagent.4. The process of claim 3 , wherein the peptide coupling reagent is selected from one or more of the group consisting of dicyclohexylcarbodiimide (DCC) claim 3 , 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) claim 3 , benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) claim 3 , and O-(1H-benzotriazol-1-yl)-N claim 3 ,N claim 3 ,N′N′-tetramethyluronium tetrafluoroborate (TBTU).5. The process of claim 1 , further comprising converting the carboxylic acid moiety of compound (ii) to an activated ester or acid halide prior to the reaction of step (1).6. The process of claim 5 , wherein said activated ester or acid halide is an O—(N-hydroxysuccinnimide) ester.7. The process of claim 1 , wherein the reaction of step (3) is conducted in the presence of a solvent.8. The process of claim 7 , wherein the solvent is tetrahydrofuran.9. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an aqueous mineral acid.10. The process of claim 9 , wherein the mineral acid is hydrochloric acid.11. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an organic boronic acid acceptor.12. The process of claim 11 , wherein the organic boronic acid acceptor is i-BuB(OH).13. The process of claim 1 , wherein the reaction of step (5) is conducted in the presence of a solvent selected from the group consisting of ethyl ...

Подробнее
14-02-2019 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20190048028A1
Принадлежит:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 2. The process of claim 1 , wherein the reaction of step (1) or step (3) or both is conducted in the presence of a peptide coupling reagent.3. The process of claim 2 , wherein the peptide coupling reagent is selected from the group consisting of a carbodiimide reagent claim 2 , phosphonium reagent claim 2 , and uronium reagent.4. The process of claim 3 , wherein the peptide coupling reagent is selected from one or more of the group consisting of dicyclohexylcarbodiimide (DCC) claim 3 , 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) claim 3 , benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) claim 3 , and O-(1H-benzotriazol-1-yl)-N claim 3 ,N claim 3 ,N′N′-tetramethyluronium tetrafluoroborate (TBTU).5. The process of claim 1 , further comprising converting the carboxylic acid moiety of compound (ii) to an activated ester or acid halide prior to the reaction of step (1).6. The process of claim 5 , wherein said activated ester or acid halide is an O—(N-hydroxysuccinnimide) ester.7. The process of claim 1 , wherein the reaction of step (3) is conducted in the presence of a solvent.8. The process of claim 7 , wherein the solvent is tetrahydrofuran.9. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an aqueous mineral acid.10. The process of claim 9 , wherein the mineral acid is hydrochloric acid.11. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an organic boronic acid acceptor.12. The process of claim 11 , wherein the organic boronic acid acceptor is i-BuB(OH).13. The process of claim 1 , wherein the reaction of step (5) is conducted in the presence of a solvent selected from the group consisting of ethyl ...

Подробнее
23-05-2019 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20190152997A1
Принадлежит:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 131.-. (canceled)33. A pharmaceutical composition comprising a compound of claim 32 , or pharmaceutically acceptable salt thereof claim 32 , and a pharmaceutically acceptable carrier.34. The pharmaceutical composition of claim 33 , wherein the compound is present in an amount of about 0.2% to about 12% by weight as a percentage of total weight.35. The pharmaceutical composition of claim 33 , wherein the compound of formula (II) is present in an amount of about 0.2% to about 3% by weight as a percentage of total weight.36. The pharmaceutical composition of claim 33 , wherein the pharmaceutical composition optionally comprising a buffer.37. The pharmaceutical composition of claim 33 , wherein the pharmaceutical composition optionally comprising sodium citrate claim 33 , or citric acid claim 33 , or mixtures thereof.38. The pharmaceutical composition of claim 33 , wherein the compound is formed in situ from the corresponding boronic acid.40. The pharmaceutical composition of claim 39 , further comprising the boronic acid of formula (VIII-15).41. The pharmaceutical composition of any one of - claim 39 , wherein the pH of the pharmaceutical composition is between about pH 4.7 and pH 6.1.42. The pharmaceutical composition of claim 41 , wherein the pH is adjustable using an inorganic acid or organic acid.43. The pharmaceutical composition of claim 33 , wherein the composition is manufactured by a granulating claim 33 , mixing claim 33 , dissolving claim 33 , encapsulating claim 33 , lyophilizing claim 33 , or emulsifying process.44. The pharmaceutical composition of claim 43 , wherein the composition is manufactured by a lyophilizing process.45. The pharmaceutical composition of any one of - claim 43 , wherein the ...

Подробнее
01-07-2021 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20210198289A1
Принадлежит:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 2. The process of claim 1 , wherein the reaction of step (1) or step (3) or both is conducted in the presence of a peptide coupling reagent.3. The process of claim 2 , wherein the peptide coupling reagent is selected from the group consisting of a carbodiimide reagent claim 2 , phosphonium reagent claim 2 , and uronium reagent.4. The process of claim 3 , wherein the peptide coupling reagent is selected from one or more of the group consisting of dicyclohexylcarbodiimide (DCC) claim 3 , 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) claim 3 , benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) claim 3 , and Of 1H-benzotriazol-1-yl-N claim 3 ,N claim 3 ,N′ claim 3 ,N′-tetramethyluronium tetrafluoroborate (TBTU).5. The process of claim 1 , further comprising converting the carboxylic acid moiety of compound (ii) to an activated ester or acid halide prior to the reaction of step (1).6. The process of claim 5 , wherein said activated ester or acid halide is an O-(N-hydroxysuccinnimide) ester.7. The process of claim 1 , wherein the reaction of step (3) is conducted in the presence of a solvent.8. The process of claim 7 , wherein the solvent is tetrahydrofuran.9. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an aqueous mineral acid.10. The process of claim 9 , wherein the mineral acid is hydrochloric acid.11. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an organic boronic acid acceptor.12. The process of claim 11 , wherein the organic boronic acid acceptor is i-BuB(OH).13. The process of claim 1 , wherein the reaction of step (5) is conducted in the presence of a solvent selected from the group consisting ...

Подробнее
11-06-2020 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20200181176A1
Принадлежит:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 2. The process of claim 1 , wherein the reaction of step (1) or step (3) or both is conducted in the presence of a peptide coupling reagent.3. The process of claim 2 , wherein the peptide coupling reagent is selected from the group consisting of a carbodiimide reagent claim 2 , phosphonium reagent claim 2 , and uronium reagent.4. The process of claim 3 , wherein the peptide coupling reagent is selected from one or more of the group consisting of dicyclohexylcarbodiimide (DCC) claim 3 , 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) claim 3 , benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) claim 3 , and O-(1H-benzotriazol-1-yl)-N claim 3 ,N′ claim 3 ,N′-tetramethyluronium tetrafluoroborate (TBTU).5. The process of claim 1 , further comprising converting the carboxylic acid moiety of compound (ii) to an activated ester or acid halide prior to the reaction of step (1).6. The process of claim 5 , wherein said activated ester or acid halide is an O—(N-hydroxysuccinnimide) ester.7. The process of claim 1 , wherein the reaction of step (3) is conducted in the presence of a solvent.8. The process of claim 7 , wherein the solvent is tetrahydrofuran.9. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an aqueous mineral acid.10. The process of claim 9 , wherein the mineral acid is hydrochloric acid.11. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an organic boronic acid acceptor.12. The process of claim 11 , wherein the organic boronic acid acceptor is i-BuB(OH).13. The process of claim 1 , wherein the reaction of step (5) is conducted in the presence of a solvent selected from the group consisting of ethyl ...

Подробнее
26-07-2018 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20180208609A1
Принадлежит:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 2. The process of claim 1 , wherein the reaction of step (1) or step (3) or both is conducted in the presence of a peptide coupling reagent.3. The process of claim 2 , wherein the peptide coupling reagent is selected from the group consisting of a carbodiimide reagent claim 2 , phosphonium reagent claim 2 , and uronium reagent.4. The process of claim 3 , wherein the peptide coupling reagent is selected from one or more of the group consisting of dicyclohexylcarbodiimide (DCC) claim 3 , 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) claim 3 , benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) claim 3 , and O-(1H-benzotriazol-1-yl)-N claim 3 ,N claim 3 ,N′ claim 3 ,N′-tetramethyluronium tetrafluoroborate (TBTU).5. The process of claim 1 , further comprising converting the carboxylic acid moiety of compound (ii) to an activated ester or acid halide prior to the reaction of step (1).6. The process of claim 5 , wherein said activated ester or acid halide is an O—(N-hydroxysuccinnimide) ester.7. The process of claim 1 , wherein the reaction of step (3) is conducted in the presence of a solvent.8. The process of claim 7 , wherein the solvent is tetrahydrofuran.9. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an aqueous mineral acid.10. The process of claim 9 , wherein the mineral acid is hydrochloric acid.11. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an organic boronic acid acceptor.12. The process of claim 11 , wherein the organic boronic acid acceptor is i-BuB(OH).13. The process of claim 1 , wherein the reaction of step (5) is conducted in the presence of a solvent selected from the group consisting ...

Подробнее
20-11-2014 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20140343314A1
Принадлежит:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 2. The process of claim 1 , wherein the reaction of step (1) or step (3) or both is conducted in the presence of a peptide coupling reagent.3. The process of claim 2 , wherein the peptide coupling reagent is selected from the group consisting of a carbodiimide reagent claim 2 , phosphonium reagent claim 2 , and uronium reagent.4. The process of claim 3 , wherein the peptide coupling reagent is selected from one or more of the group consisting of dicyclohexylcarbodiimide (DCC) claim 3 , 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) claim 3 , benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) claim 3 , and O-(1H-benzotriazol-1-yl)-N claim 3 ,N claim 3 ,N′N′-tetramethyluronium tetrafluoroborate (TBTU).5. The process of claim 1 , further comprising converting the carboxylic acid moiety of compound (ii) to an activated ester or acid halide prior to the reaction of step (1).6. The process of claim 5 , wherein said activated ester or acid halide is an O—(N-hydroxysuccinimide) ester.7. The process of claim 1 , wherein the reaction of step (3) is conducted in the presence of a solvent.8. The process of claim 7 , wherein the solvent is tetrahydrofuran.9. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an aqueous mineral acid.10. The process of claim 9 , wherein the mineral acid is hydrochloric acid.11. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an organic boronic acid acceptor.12. The process of claim 11 , wherein the organic boronic acid acceptor is i-BuB(OH).13. The process of claim 1 , wherein the reaction of step (5) is conducted in the presence of a solvent selected from the group consisting of ethyl ...

Подробнее
27-11-2014 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: US20140349966A1
Принадлежит: Millennium Pharmaceuticals, Inc.

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
06-08-2020 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20200247829A1
Принадлежит:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 131.-. (canceled)33. The method of claim 32 , wherein the alpha- or beta-hydroxy carboxylic acid is citric acid.34. The method of claim 33 , wherein the aqueous solution comprises water and water-miscible co-solvent.35. The method of claim 34 , wherein the water-miscible co-solvent comprise tert-butyl alcohol claim 34 , methanol claim 34 , ethanol claim 34 , or any mixture thereof.36. The method of claim 33 , wherein the lyophilized powder further comprises and a compound of formula (v).37. The method of claim 36 , wherein the lyophilized powder further comprises free citric acid.38. The method of claim 32 , wherein an equilibrium is established between the compound of formula (I) and the compound of formula (v) upon reconstitution of the lyophilized powder in a reconstitution solvent.40. The method of claim 39 , wherein the alpha- or beta-hydroxy carboxylic acid is citric acid.41. The method of claim 39 , wherein the aqueous mixture further comprises water and a water-miscible co-solvent.42. The method of claim 41 , wherein the water-miscible co-solvent comprise tert-butyl alcohol claim 41 , methanol claim 41 , ethanol claim 41 , or any mixture thereof.43. The method of claim 41 , wherein the aqueous mixture further comprises a buffer.44. The method of claim 43 , wherein the buffer is sodium citrate claim 43 , citric acid claim 43 , or mixture thereof.45. The method of claim 40 , wherein the lyophilized pharmaceutical composition further comprises free citric acid.47. The method of claim 46 , wherein an equilibrium is established between the compound of formula (I) and the compound of formula (v) upon reconstitution in a reconstitution solvent. This application is a divisional of U.S. Utility patent application Ser. ...

Подробнее
29-08-2019 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20190263839A1
Принадлежит:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 2. The process of claim 1 , wherein the reaction of step (1) or step (3) or both is conducted in the presence of a peptide coupling reagent.3. The process of claim 2 , wherein the peptide coupling reagent is selected from the group consisting of a carbodiimide reagent claim 2 , phosphonium reagent claim 2 , and uronium reagent.4. The process of claim 3 , wherein the peptide coupling reagent is selected from one or more of the group consisting of dicyclohexylcarbodiimide (DCC) claim 3 , 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) claim 3 , benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) claim 3 , and O-(1H-benzotriazol-1-yl)-N claim 3 ,N′ claim 3 ,N′-tetramethyluronium tetrafluoroborate (TBTU).5. The process of claim 1 , further comprising converting the carboxylic acid moiety of compound (ii) to an activated ester or acid halide prior to the reaction of step (1).6. The process of claim 5 , wherein said activated ester or acid halide is an O—(N-hydroxysuccinnimide) ester.7. The process of claim 1 , wherein the reaction of step (3) is conducted in the presence of a solvent.8. The process of claim 7 , wherein the solvent is tetrahydrofuran.9. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an aqueous mineral acid.10. The process of claim 9 , wherein the mineral acid is hydrochloric acid.11. The process of claim 1 , wherein the reaction of step (4) is conducted in the presence of an organic boronic acid acceptor.12. The process of claim 11 , wherein the organic boronic acid acceptor is i-BuB(OH).13. The process of claim 1 , wherein the reaction of step (5) is conducted in the presence of a solvent selected from the group consisting of ethyl ...

Подробнее
29-10-2015 дата публикации

BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

Номер: US20150307523A9
Принадлежит:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. 6. The method of claim 1 , wherein the cancer is multiple myeloma claim 1 , or a recurrence of multiple myeloma.7. The method of claim 1 , wherein the cancer is lymphoma claim 1 , or a recurrence of lymphoma.8. The method of claim 1 , wherein the patient in need of the treatment is a patient having or at risk of developing or experiencing a recurrence in a cancer selected from multiple myeloma and lymphoma.98. The method according to any one of - claims 1 , wherein the compound of formula (II) is administered with another therapeutic agent.10. The method of claim 9 , wherein the other therapeutic agent is melphalan.11. The method of claim 9 , wherein the other therapeutic agent is lenalidomide.12. The method of claim 1 , wherein the compound or pharmaceutical composition is administered orally claim 1 , parenterally claim 1 , by inhalation spray claim 1 , topically claim 1 , rectally claim 1 , nasally claim 1 , buccally claim 1 , vaginally claim 1 , or via an implanted reservoir.13. The method of claim 12 , wherein the compound is administered orally.14. The method of claim 12 , wherein the compound is administered intravenously.15. The method of claim 12 , wherein the compound is administered systemically or locally.21. The pharmaceutical composition of claim 16 , wherein the compound of formula (II) is present in an amount of about 0.2% to about 12% claim 16 , by weight as a percentage of total weight.22. The pharmaceutical composition of claim 16 , wherein the compound of formula (II) is present in an amount of about 0.2% to about 3% claim 16 , by weight as a percentage of total weight.23. The pharmaceutical composition of claim 16 , wherein the compound of formula (II) is present in an amount of about 0.25% to ...

Подробнее
17-12-2020 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: US20200392164A1
Принадлежит: Millennium Pharmaceuticals Inc

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
09-04-2020 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: JP2020055829A
Принадлежит: Millennium Pharmaceuticals Inc

【課題】プロテアソーム阻害剤として有用なボロン酸エステル化合物を提供する。【解決手段】式(I)の化合物を提供する。(式中、Z1およびZ2は共に、α−ヒドロキシカルボン酸に由来する部分を形成し、いずれの場合にもホウ素に付着する原子は、酸素原子であるか、またはZ1およびZ2は共に、β−ヒドロキシカルボン酸に由来する部分を形成し、いずれの場合にもホウ素に付着する原子は、酸素原子である)。また、これを含む医薬組成物、および様々な疾患の治療における組成物の使用方法も提供する。別の態様では、式(I)の化合物、またはその結晶形態、および追加の賦形剤を含む、医薬組成物を提供し、これは、経口医薬投薬形態を製造するのに好適である。別の態様では、式(I)の化合物、またはその結晶形態、および追加の賦形剤を含む、医薬組成物を提供し、これは、凍結乾燥粉末の医薬投薬形態を製造するのに好適である。【選択図】なし

Подробнее
19-04-2016 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: CA2727862C
Принадлежит: Millennium Pharmaceuticals Inc

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
07-01-2020 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: US10526351B2
Принадлежит: Millennium Pharmaceuticals Inc

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
13-11-2015 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: MY155592A
Принадлежит: Millennium Pharm Inc

THE PRESENT INVENTION PROVIDES NOVEL COMPOUNDS USEFUL AS PROTEASOME INHIBITORS. THE INVENTION ALSO PROVIDES PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS OF THE INVENTION AND METHODS OF USING THE COMPOSITIONS IN THE TREATMENT OF VARIOUS DISEASES.

Подробнее
03-11-2015 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: US9175018B2
Принадлежит: Millennium Pharmaceuticals Inc

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
01-09-2014 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: TW201433317A
Принадлежит: Millennium Pharm Inc

本發明提供適用作蛋白酶體抑制劑之新穎化合物。本發明亦提供包含本發明之化合物之醫藥組合物,及使用該組合物治療各種疾病之方法。

Подробнее
08-01-2019 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: CA2921946C
Принадлежит: Millennium Pharmaceuticals Inc

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
09-05-2013 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: AU2013204518A1
Принадлежит: Millennium Pharmaceuticals Inc

H:\fmt\Intenvoven\NRPortbI\DCC\FhMS067099_1.DOC- 1/04/2013 The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
11-08-2017 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof.

Номер: MX349769B
Принадлежит: Millennium Pharm Inc

La presente invención provee compuestos novedosos útiles como inhibidores de proteasoma. La invención además provee composiciones farmacéuticas que comprenden los compuestos de la invención y métodos para utilizar las composiciones en el tratamiento de varias enfermedades.

Подробнее
10-08-2018 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof.

Номер: MX358222B
Принадлежит: Millennium Pharm Inc

La presente invención provee compuestos novedosos útiles como inhibidores de proteasoma. La invención además provee composiciones farmacéuticas que comprenden los compuestos de la invención y métodos para utilizar las composiciones en el tratamiento de varias enfermedades.

Подробнее
01-11-2022 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: US11485746B2
Принадлежит: Takeda Pharmaceutical Co Ltd

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
03-11-2015 дата публикации

processes for the generation of boronate ester compounds and said compounds

Номер: BR122014008754A2
Принадлежит: Millennium Pharm Inc

resumo processos para a geração de compostos de éster boronato e ditos compostos a presente invenção fornece novos compostos úteis como inibidores do proteassoma. a invenção também fornece composições farmacêuticas que compreendem os compostos da invenção e métodos de utilização das composições no tratamento de várias doenças. Summary Methods for Generating Boronate Ester Compounds and Said Compounds The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
23-09-2019 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: MY171021A
Принадлежит: Millennium Pharm Inc

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
31-12-2009 дата публикации

Boronate ester compounds and pharmaceutical compositions thereof

Номер: US20090325903A1
Принадлежит: Millennium Pharmaceuticals Inc

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
26-10-2023 дата публикации

ボロン酸エステル化合物およびその医薬組成物

Номер: JP2023158150A
Принадлежит: Millennium Pharmaceuticals Inc

【課題】プロテアソーム阻害剤として有用なボロン酸エステル化合物を提供すること。【解決手段】本発明は、プロテアソーム阻害剤として有用な新規化合物を提供する。本発明はまた、本発明の化合物を含む医薬組成物、および様々な疾患の治療における組成物の使用方法も提供する。別の態様では、本発明は、式(I)の化合物、またはその結晶形態、および本明細書に記載の追加の賦形剤を含む、医薬組成物を提供し、これは、経口医薬投薬形態を製造するのに好適である。別の態様では、本発明は、式(I)の化合物、またはその結晶形態、および本明細書に記載の追加の賦形剤を含む、医薬組成物を提供し、これは、凍結乾燥粉末の医薬投薬形態を製造するのに好適である。【選択図】なし

Подробнее